Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Authors:
- Verònica FernàndezVFVerònica Fernàndez
- Victor MorenoVMVictor Moreno
- Joan VallsJVJoan Valls
- Luis HernándezLuis Hernández
- Francesc BoschFBFrancesc Bosch
- Pau AbrisquetaPAPau Abrisqueta
- Wolfram KlapperWKWolfram Klapper
- Martin DreylingMDMartin Dreyling
- Eva HosterEHEva Hoster
- Hans Konrad Müller-HermelinkHMHans Konrad Müller-Hermelink
- German OttGOGerman Ott
- 20 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (30) , 4966-4972
Abstract
Purpose Despite the common underlying translocation t(11;14) involving cyclin D1 that is present in nearly all cases of mantle-cell lymphoma (MCL), the clinical course of the disease is highly variable. The aim of the present study was to develop a quantitative gene expression–based model to predict survival in newly diagnosed patients with MCL that involves a minimum number of genes and is applicable to fresh-frozen and formalin-fixed, paraffin-embedded (FFPE) tumor samples. Patients and Methods The expression of 33 genes with potential prognostic and pathogenetic impact in MCL was analyzed using quantitative reverse-transcription polymerase chain reactions (qRT-PCR) in a low-density array format in frozen tumor samples from 73 patients with MCL. Multivariate Cox methods and stepwise algorithms were applied to build gene expression-based survival predictors. An optimized five-gene model was subsequently applied to FFPE tumor samples from 13 patients with MCL from the initial series and to 42 independent MCL samples. Results The optimized survival predictor was composed of the five genes RAN, MYC, TNFRSF10B, POLE2, and SLC29A2 and was validated for application in FFPE tissue samples. It allowed the survival prediction of patients with MCL with widely disparate clinical outcome and was superior to the immunohistochemical marker Ki-67, an established prognostic factor in MCL. Conclusion We here present a validated qRT-PCR–based test for survival prediction in patients with MCL that is applicable to fresh frozen as well as to FFPE tissue specimens. This test may prove useful to guide individualized treatment approaches for patients with MCL.Keywords
This publication has 51 references indexed in Scilit:
- Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysisBlood, 2007
- Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression–Based Proliferation SignatureJournal of Clinical Oncology, 2007
- Update on the molecular biology of mantle cell lymphomaHematological Oncology, 2006
- Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response PathwaysJournal of Clinical Oncology, 2005
- Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcomeBlood, 2005
- The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaCancer Cell, 2003
- From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decadesHuman Pathology, 2002
- Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtypeLeukemia, 2001
- Mantle cell lymphomaCancer, 1998
- p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)Blood, 1995